Search

Displaying results 3471 - 3480 of 8700 in total
  1. Target

    Integrin alpha-M

    go.drugbank.com/bio_entities/BE0010412
    TargetHumans

    May regulate phagocytosis-induced apoptosis in extravasated neutrophils (By similarity). May play a role in mast cell development (By similarity). … It is identical with CR-3, the receptor for the iC3b fragment of the third complement component. It probably recognizes the R-G-D peptide in C3b.

    Synonyms: Cell surface glycoprotein MAC-1 subunit alpha, Neutrophil adherence receptor
  2. Drug

    Ticarcillin

    go.drugbank.com/drugs/DB01607
    ApprovedVet approvedWithdrawn

    An antibiotic derived from penicillin similar to carbenicillin in action.

    Categories: Antibacterials for Systemic Use, Antiinfectives for Systemic Use
  3. Drug

    Dimazole

    go.drugbank.com/drugs/DB13858
    ApprovedWithdrawn

    Dimazole (diamthazole) is an antifungal. It was withdrawn in Franch in 1972 due to neuropsychiatric reactions.

    Categories: Antifungals for Topical Use, Antifungals for Dermatological Use
  4. Drug

    Ioxitalamic acid

    go.drugbank.com/drugs/DB13444
    ApprovedWithdrawn

    Ioxitalamate is an ionic iodinated contrast medium.[A27209] It is a first-generation contrast media formed by an ionic monomer with a high osmolarity of 1500-1800 mOsm/kg.

  5. Drug

    Streptozocin

    go.drugbank.com/drugs/DB00428
    ApprovedInvestigational

    An antibiotic that is produced by Stretomyces achromogenes. It is used as an antineoplastic agent and to induce diabetes in experimental animals.

    Categories: P-glycoprotein inducers, Cytochrome P-450 CYP1A2 Inducers
  6. Drug

    Revumenib

    go.drugbank.com/drugs/DB18515
    ApprovedInvestigational

    [A264688] Revumenib is an oral small molecule menin inhibitor that prevents the interaction between menin and aberrant KMT2A. … [L51888] In October of 20225, it was approved for myeloid leukemia patients with nucleophosmin 1 (NPM1) mutations. [L54376]

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Inhibitors
  7. Drug

    Sulfathiazole

    go.drugbank.com/drugs/DB06147
    ApprovedVet approvedWithdrawn

    Except for those formulated for vaginal use, the FDA withdrew its approval for the use of all drug products containing sulfathiazole.[L43942]

    Categories: Antibacterials for Systemic Use, Antiinfectives for Systemic UseSynonyms: 2-(p-Aminobenzenesulfonamido)thiazole, 2-(p-Aminobenzenesulphonamido)thiazole
  8. Drug

    Maxy-G34

    go.drugbank.com/drugs/DB05718
    Investigational

    It is being developed by Maxygen, Inc. for the treatment of chemotherapy-induced neutropenia.

  9. Drug

    Triplizumab

    go.drugbank.com/drugs/DB30669
    Investigational

    triplizumab is a biologic drug. triplizumab is under investigation in clinical trial NCT06486220 (PFLL Combined With PD-1 Antibody With or Without FMT for Oligometastatic NPC,a Phase III ,Open, Randomized

  10. Drug

    Cedazuridine

    go.drugbank.com/drugs/DB15694
    ApprovedInvestigational

    [A215107, A215112, A215117, A215127, L14897] Cedazuridine was first reported in 2014,[A215107] and was subsequently approved by the FDA on July 7, 2020, in combination with [decitabine] for sale by